Quest Diagnostics benefits from an aging population, driving increased lab testing volumes, and offers 2.0% dividend yield.

Lab operator Quest Diagnostics said on Wednesday it will launch a test for H5N1 bird flu at the end of October after the U.S.

Quest Diagnostics (NYSE:DGX) announced on Wednesday that it will roll out a rapid molecular lab test to detect the avian ...

Quest Diagnostics reported strong third-quarter earnings driven by acquisitions, with revenue surpassing expectations, though ...

Argus raised the firm’s price target on Quest Diagnostics (DGX) to $175 from $163 and keeps a Buy rating on the shares. The company ...

Quest Diagnostics reported strong Q3 earnings, with an 8.5% revenue increase and a 3.6% rise in diluted EPS. Read why I ...

Leerink Partners analyst Michael Cherny has reiterated their neutral stance on DGX stock, giving a Hold rating yesterday. Michael Cherny has ...

The not-for-profit charitable health group of the United Methodist Church will transition its outreach testing to the ...

Quest Diagnostics reports strong Q3 with 8.5% sales growth, raises 2024 revenue guidance to $9.80 billion-$9.85 billion, ...

Q3 2024 Earnings Call Transcript October 22, 2024 Quest Diagnostics Incorporated beats earnings expectations. Reported EPS is ...

Quest has developed a multi-target molecular test for avian influenza A H5 virus that it plans to make available by the end of October.

SECAUCUS, N.J. (AP) — SECAUCUS, N.J. (AP) — Quest Diagnostics Inc. (DGX) on Tuesday reported third-quarter earnings of $226 million. On a per-share basis, the Secaucus, New Jersey-based company said ...